Tonix Pharmaceuticals (TNXP) - 2023 Q2 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 For the Transition Period from _________ to _________ or Commission file number: 001-36019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 TONIX PHARMACEUTICALS HOLDING CORP. (Address of Principal Executive Offices) (Zip Code) (862) 799-9155 ...